130999MOTI1001: Oncojan based drug candidate for the treatment of ovarian cancerClosedFeasibility StudiesInnovate UKOne in three of us will get cancer and increases in life expectancy indices will only exacerbate this statistic. Unfortunately, many cancer subtypes have very poor survival rates. Most chemotherapeutics have devastating side effects such as hair loss, nausea, weakened immunity and fatigue. BioMoti is developing an exciting technology platform based on Queen Mary, University of London research to improve the delivery of anti-cancer drugs to cancer cells and spare healthy tissues. Initial laboratory tests proved this new approach dramatically increases the efficacy of chemotherapy whilst significantly reducing associated side effects. This TSB Biomedical Catalyst project will investigate the feasibility of developing a lead candidate for the treatment of ovarian cancer based on the platform technology. Looking forward, the conceptual demonstration of the technology and widespread adoption would lead to substantial patient benefits in a number of cancer types.